CURRICULUM VITAE KENNETH D. CHINSKY, M.D.

Size: px
Start display at page:

Download "CURRICULUM VITAE KENNETH D. CHINSKY, M.D."

Transcription

1 KENNETH D. CHINSKY, M.D. Chest Diseases of Northwestern PA 3580 Peach Street, Suite 103A Erie, PA Phone: (814) FAX: (814) Home Address 5525 Shadybrook Drive and Phone: Erie, PA (814) Birthdate: 10/06/60 Personal: Employment: Born in St. Louis, MO Married, 3 children. Wife has a master's degree in early childhood special education. Chest Diseases of Northwestern PA Private Practice 7/91-present Education: Undergraduate: University Missouri-Columbia Honors- Freshman Curator's Scholar , University Scholar , Who's Who Among American College Students 1981 Medical: University Missouri-Columbia Professional: Postgraduate: Internship/Residency-Internal Medicine at The Jewish Hospital of St. Louis 6/85-6/88 Fellowship-Pulmonary and Critical Care Medicine at Washington University Medical Center 7/88-6/91 Attending Physician, Emergency Room at The Jewish Hospital of St. Louis 7/89-6/91 Attending Physician, Medical Intensive Care Unit and Pulmonary Consult services at The Jewish Hospital of St. Louis and John Cochran VA Hospital of St. Louis 7/90-6/91

2 Page 2 Professional: (cont) Positions held at St. Vincent Health Center Erie, PA: Director, Intensive Care Unit Chairman, Critical Care Committee Chairman, Ethics Committee Chairman, Credentials Committee Infection Control Committee 1991-present Medical Staff Leadership including Secretary-Treasurer , Vice-President , President Medical Executive Committee 1994-present Tuberculosis Clinician, Erie County, PA 1991-present Tuberculosis Clinician, Chautauqua County, NY Licensure and Diplomate, National Board of Medical Examiners Board Certification: 1986 Diplomate, American Board of Internal Medicine 1988 Diplomate, American Board of Internal Medicine: -Pulmonary 1990, recertified 1999 and Critical Care Medicine 1991, recertified 1999 and 2009 Pennsylvania license: MD043792L Research: Professional Societies: Comparison of intermittent mandatory ventilation with and without pressure support ventilation for weaning patients from mechanical ventilation. Presented at symposium, "New trends in mechanical ventilation", at 1991 International Conference of American Thoracic Society. Member, Society of Critical Care Medicine Fellow, American College of Chest Physicians Phi Delta Epsilon Medical Fraternity AMA, Pennsylvania Medical Society, Erie County Medical Society Community: WQLN Board of Directors-Public Radio-TV Various positions including Chairperson

3 Page 3 Community: (continued) Awards: Invited Reviewer: Sarah Reed Children s Center Board 2008-present Golden Apple for outstanding clinical educator Saint Vincent Health Center 1992, 2000, and 2009 CHEST Am J Infection Cont Publications: 1. Chinsky K. Goodenberger DM: Use of Indium -- labeled white blood cell scan to diagnose cytomegalovirus pneumonia in a renal transplant recipient with a normal chest radiograph. CHEST 1991; 99: Chinsky KD, St. John RE, Lefrak SS: A randomized, prospective comparison of intermittent mandatory ventilation (IMV) weaning with and without pressure support ventilation (PSV). Amer Rev Respir Dis 1991; 143: A Chinsky, K. The Best Part of Practice is the Friendship of Patients. Medical Economics. 1999; 76: Chinsky K. Critical Interactions Man and Machine. CHEST 2001; 119: Chinsky K. Ventilator-Associated Pneumonia. CHEST 2002; 122: Chinsky K. Unlocking an Effective Approach to Ventilator-Associated Pneumonia. Adv Managers Resp Care 2003; 12: Chinsky K. Getting In: A Primer on Entering Private Practice. Adv Managers Resp Care. 2004; 13: Chinsky K. The evolving paradigm of hyperglycemia and critical illness. CHEST 2004; 126: Chinsky K. Varying approaches to tracheostomy. Vive la difference. CHEST 2005; 127: Chinsky K. Bleeding risk and bronchoscopy: In search of the evidence in evidence-based medicine. CHEST 2005; 127:

4 Page Anzueto A, Ferguson G, Feldman G, Seibert A, Chinsky K, Emmett A, Crater G, Crater G, Knobil K, O Dell D, Kalberg C. A Randomized, Double-Blind Trial Comparing the Effect of Fluticasone/Salmeterol 250/50 with Salmeterol on COPD Exacerbations. Abstract accepted at poster session American Thoracic Society Chinsky K. How to Get Started in Research. Adv Managers Resp Care 2008; 17: Chinsky, K. Challenges in Diagnosing Ventilator-Associated Pneumonia. (podcast) Accessed 10/1/ Anzueto A. Ferguson G, Feldman G, Chinsky K, Seibert A, Emmett, A, Knobil K, O Dell D, Kalberg C, Crater G. Effect of Fluticasone Propionate/ Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes. COPD 2009; 6: Clinical Research Trials: 1. A Randomized, 12-week, Double-blind, Placebo-controlled, parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding Cilomilast (ARIFLO) 15 mg. Twice Daily to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) 2. A 52-week, randomized, double-blind, single-dummy, parallel group, multicenter Phase III study comparing the long-term safety of SYMBICORT pmdi 160/4.5 ug x 4 actuations twice daily to SYMBICORT pmdi 160/4.5 ug x 2 actuations twice daily and budesonide HFA pmdi 160 ug x 4 actuations twice daily in adult and adolescent subjects with asthma 3. A Placebo-Controlled Comparison of Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated with Inhaled Steroids 4. A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo and Active Controlled Study of SYMBICORT pmdi Administered Once Daily in Adults and Adolescents with asthma

5 Kenneth D. Chinsky, MD Page 5 5. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Determine the Efficacy of Oral Zafirlukast (ACCOLATE ) When Administered According to Current Labeling Instructions or Simplified Dosing Instructions in Subjects With Asthma Receiving Inhaled B2-Agonist in Combination With Inhaled Corticosteroids (ICS) 6. A Randomized, Double-Blind, Double-Dummy, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Oral SB mg. Once Daily for 7 Days Versus Oral Levofloxacin 500 mg. Once Daily for 7 Days for the Treatment of Acute Exacerbation of Chronic Bronchitis 7. A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Safety of Grepafloxacin (Raxar ) in the Treatment of Patients with Community Acquired Pneumonia 8. A 12-Week, Randomized, Double-Blind, Positive Control, Crossover Study of Albuterol, Ipratropium, and the Combination, as an Inhalation Solution in Patients with Chronic Obstructive Pulmonary Disease 9. A Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older with Asthma 10. A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of ARIFLO (15 mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 11. A Randomized, Double-Blind, Parallel Group, 52-week Study to Compare the Effect of the Fluticasone Propionate/Salmeterol Diskus Combination Product 250/50 mcg BID with Salmeterol Diskus 50 mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with COPD 12. A 6-Month Double-blind, Double-dummy, Randomized, Parallel group, Multicenter Efficacy and Safety Study of Symbicort pmdi 2 x 160/4.5 mg bid and 2 x 80/4.5 mg bid Compared to Formoterol TBH, Budesonide pmdi (& the combination) & Placebo in COPD patients 13. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Elderly Patients with Primary Insomnia 14. A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK-0928 in Adult Patients with Primary Insomnia

6 Page A Randomized, Double-Blind Trial Comparing the Effect of Fluticasone/Salmeterol 250/50 with Salmeterol on COPD Exacerbations 16. A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg. BID and Fluticasone Propionate (FP) DISKUS 250 mcg. BID in Treatment of Subjects with Asthma 17. A 26-week treatment, multi center, randomized, double-blind, double dummy, placebo-controlled, adaptive, seamless, parallel-group study to assess the efficacy, safety and tolerability of two doses of indacaterol (selected from 75, 150, 300 & 600 ug o.d.) in patients with chronic obstructive pulmonary disease using blinded formoterol (12 ug b.i.d.) and open label tiotropium (18 ug o.d.) as active controls. (Protocol No.: CQAB149B2335S) 18. A 12-week treatment, multi center, randomized, double-blind, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 ug o.d.) in patients with chronic obstructive pulmonary disease. (Protocol No.: CQAB149B2346) 19. A Phase IIb clinical trial to evaluate the safety, tolerability and immunogenicity of Zoster vaccine in patients on chronic/maintenance corticosteroids. (Protocol No.: V ) 20. A randomized, double-blind, parallel group 12-week comparison of the efficacy and safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a metered-dose-inhaler 230/42 mcg twice-daily with Fluticasone Propionate/Salmeterol DISKUS 250/50 mcg twice-daily in subjects with COPD. (Protocol No.: ADC ) 21. A double-blind, randomized, placebo-controlled, multi center, parallel group, dose-ranging study of MK-0633 in adult patients with Chronic Asthma (Protocol No.: ) 22. A 52-week, randomized, double-blind, parallel-group study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in Treatment of Subjects with Asthma (Protocol: ADA109057)

7 Page A multicenter, randomized, double-blind, placebo-controlled, parallel group, 4- week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of the Combination of GSK and GW administered once-daily in Subjects With COPD (Protocol: DB ) 24. A randomized, double-blind, parallel-group, 24-week study to evaluate the efficacy and safety of ADVAIR DISKUS (Fluticasone Propionate/Salmeterol Combination Product 250/50 mcg Inhalation Powder) BID plus Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder 18mcg) QD versus Spiriva QD plus Placebo DISKUS BID in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (Protocol: ADC111114) 25. A randomized, double-blind, controlled, parallel group, 12 week treatment study to compare the efficacy and safety of the combination of indacaterol 150 µg once daily with open label tiotropium 18µg once daily versus open label tiotropium 18µg once daily in patients with moderate-to-severe chronic obstructive pulmonary disease (Protocol No.: CQAB149B2351) 26. Efficacy and safety of aclidinium bromide at two dose levels (200 µg twice daily, 400µg twice daily) vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD) (Protocol: LAS-MD-33) 27. A Long-term, Randomized, Double-Blind, Extension Study of the Safety, Tolerability and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (Protocol: LAS-MD-36) 28. A randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of 2 doses of aclidinium bromide compared with placebo for 12 weeks in patients with moderate to severe, stable chronic obstructive pulmonary disease followed by a 40-week evaluation of the 2 aclidinium bromide doses (Protocol LAS-MD-38) 29. Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease (ASQ112989) 30. Novartis Pharmaceuticals trial entitled: A randomized, double-blind, doubledummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.cqab149b2357

8 Page Novartis Pharmaceuticals trial entitled: A 26-week treatment multicenter, randomized, double-blind, parallel-group, placebo and active controlled (open label) study to assess the efficacy, safety and tolerability of QVA149 (110/50 mcg q.d.) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). QVA149A A 52-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropium (18 μg o.d.) on COPD exacerbations in patients with severe to very severe chronic obstructive pulmonary disease (COPD). CQVA149A A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered by the Respimat Inhaler with Tiotropium inhalation capsules 18 µg delivered by the HandiHaler A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- Controlled Study to Evaluate the Safety and Tolerability of GSK mcg once-daily alone and in combination with GW mcg once-daily via novel Dry Powder Inhaler (ndpi) in Subjects with Chronic Obstructive Pulmonary Disease (COPD). DB A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW Inhalation Powder and the Individual Components Delivered Once-Daily via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease: DB A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating The Efficacy, Safety, and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24- Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD-31.

9 Page A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate compared with Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD A 52-week, double-blind, randomized, placebo controlled parallel group study to evaluate the effect of roflumilast 500 μg on exacerbations in severe to very severe COPD patients treated with fixed dose combination LABA/ICS (Advair 250/50 μg or, Symbicort 160/4.5 μg): ROF-MD A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or an increased risk for cardiovascular disease: HZC SUMMIT. 40. Novartis Pharmaceuticals trial entitled: A randomized, placebo-controlled, doseranging, multi-centre trial of QAW039 (1-450 mg p.o.) to investigate the effect on FEV 1 in and ACQ patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy: CQAW039A A Phase III, Long-Term, Randomized, Double-Blind, Extension Study of the Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients with Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD): LAC-MD A randomized, double blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5µg (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) compared to once daily, orally inhaled, co-administration of placebo (delivered by the Respimat Inhaler) and tiotropium 18µg (delivered by the HandiHaler ) in patients with Chronic Obstructive Pulmonary Disease (COPD): revised 1/13

Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA 16506

Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA 16506 Joseph E. Rowane, D.O. Home Address: 6073 Volkman Road Erie, PA 16506 Professional Address: Chest Diseases of Northwestern PA 3580 Peach Street--Suite 103 Erie, Pennsylvania 16508 Phone: (814) 864-4755

More information

Jeffrey P. McGovern, MD, FCCP, ABSM

Jeffrey P. McGovern, MD, FCCP, ABSM Jeffrey P. McGovern, MD, FCCP, ABSM 3580 Peach Street--Suite 103A Erie, PA 16508 814-864-4755 (Home: 814-868-1155) Date of Birth: March 10, 1960 Spouse: Kathleen Medical Licenses:, Pennsylvania MD047962L

More information

JORGE MANUEL MERCADO, M.D. Chest Diseases of Northwestern Pennsylvania 3580 Peach Street, Suite 103A Erie, PA Office:

JORGE MANUEL MERCADO, M.D. Chest Diseases of Northwestern Pennsylvania 3580 Peach Street, Suite 103A Erie, PA Office: JORGE MANUEL MERCADO, M.D. Chest Diseases of Northwestern Pennsylvania 3580 Peach Street, Suite 103A Erie, PA 16508 Office: 814-864-4755 WORK EXPERIENCE March 2011 - present Chest Diseases of Northwestern

More information

CURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP

CURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP CURRICULUM VITAE GREGORY JAMES FERREIRA M.D., FCCP Business address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, Fl Phone: 941.951.3920 Fax: 941.951.3922 Prior business

More information

CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP

CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP Present Business Address: Prior Business Address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, FL 34239 Telephone: 941-951-3920

More information

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical

II: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Guide to Inhaled Treatment Choices

Guide to Inhaled Treatment Choices Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint

More information

Ronald H. Saff, M.D. Curriculum Vitae

Ronald H. Saff, M.D. Curriculum Vitae Ronald H. Saff, M.D. Curriculum Vitae Address 2300 Centerville Road Tallahassee, FL 32308 (850) 766-7886 ronsaff@aol.com Certification Board Certified Internal Medicine, September 1992 Board Certified

More information

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor

COPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy

More information

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder

TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Test Your Inhaler Knowledge

Test Your Inhaler Knowledge A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary

More information

Wirral COPD Prescribing Guidelines

Wirral COPD Prescribing Guidelines Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed

More information

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes

COPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program

More information

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33 COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications

More information

CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP

CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP CURRICULUM VITAE TODD KEN HORIUCHI, M.D., FCCP Present Business Address: Prior Business Address: Hautamaki & Horiuchi Personal Physicians of Sarasota 1843 Floyd Street Sarasota, FL 34239 Telephone: 941-951-3920

More information

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018

Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018 Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize

More information

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits

Dual-Controller Asthma Therapy: Rationale and Clinical Benefits B/1 Dual-Controller Asthma Therapy: Rationale and Clinical Benefits MODULE B The 1997 National Heart, Lung, and Blood Institute (NHLBI) Expert Panel guidelines on asthma management recommend a 4-step approach

More information

A Visual Approach to Simplifying Respiratory Drug Regimens

A Visual Approach to Simplifying Respiratory Drug Regimens Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects

More information

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital

Choosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies

More information

Select Inhaled Respiratory Agents

Select Inhaled Respiratory Agents Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends

More information

The clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years

The clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the

More information

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years

NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled

More information

Chronic obstructive pulmonary disease (COPD) is characterized

Chronic obstructive pulmonary disease (COPD) is characterized DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment

More information

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)

QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol) Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:

More information

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS

Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Asthma/COPD Update with Inhaler Workshop

Asthma/COPD Update with Inhaler Workshop Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Asthma Updates Asthma Updates SMART Trial

More information

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:

More information

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources

Medications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency

More information

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives.

Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists. Learning Objectives. Incorporating Newer Therapies and Strategies to Improve COPD Outcomes: A Practical Guide for Pharmacists Learning Objectives Identify the risk factors for COPD and the clinical features that differentiate

More information

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)

More information

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved. Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights

More information

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18

Clinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18 Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma

More information

Common Drug Review Pharmacoeconomic Review Report

Common Drug Review Pharmacoeconomic Review Report Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Three s Company - The role of triple therapy in chronic obstructive pulmonary

Three s Company - The role of triple therapy in chronic obstructive pulmonary Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov

More information

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing

12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School

More information

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy

COPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic

More information

Inhaled Corticosteroids Drug Class Prior Authorization Protocol

Inhaled Corticosteroids Drug Class Prior Authorization Protocol Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

Diagnosis and Management of Asthma

Diagnosis and Management of Asthma Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:

More information

reslizumab (Cinqair )

reslizumab (Cinqair ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Drug Effectiveness Review Project Summary Report

Drug Effectiveness Review Project Summary Report Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Curriculum Vitae, Ward Jackson Paine, M.D. Ward Jackson Paine, M.D. Exemplar Research, Inc Mileground Road Morgantown, WV 26505

Curriculum Vitae, Ward Jackson Paine, M.D. Ward Jackson Paine, M.D. Exemplar Research, Inc Mileground Road Morgantown, WV 26505 CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Ward Jackson Paine,

More information

Year in review. Vit Perlik Director of Regulatory Science and Clinical Development

Year in review. Vit Perlik Director of Regulatory Science and Clinical Development Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration

More information

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health

Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions

More information

Asthma and COPD Drug Discoveries:

Asthma and COPD Drug Discoveries: Asthma and COPD Drug Discoveries: What the future holds World Leaders in Health Industry Analysis Asthma and COPD Drug Discoveries: what the future holds ISBN: 1 85822 264 8 Copyright 2006 Espicom Business

More information

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.

Dual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS. DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms

More information

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08

Pharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08 Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes

More information

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

COPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

Three better than 1 or 2?

Three better than 1 or 2? Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic

More information

Dose. Route. Units. Given. Dose. Route. Units. Given

Dose. Route. Units. Given. Dose. Route. Units. Given Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening

More information

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health

COPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or

More information

Presented by UIC College of Nursing

Presented by UIC College of Nursing Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.

More information

Chronic Obstructive Pulmonary Disease 1/18/2018

Chronic Obstructive Pulmonary Disease 1/18/2018 Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 07/05/18 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE: CINQAIR (reslizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Drug Use Research & Management Program Phone Fax Month/Year of Review: July 2013

Drug Use Research & Management Program Phone Fax  Month/Year of Review: July 2013 Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

The FDA Critical Path Initiative

The FDA Critical Path Initiative The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary

More information

Respiratory Inhalers. Identification Guide Version 3

Respiratory Inhalers. Identification Guide Version 3 Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical

More information

BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW

BUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

FDCs for CO PD: From Famine to a Feast of Therapeutic Choices

FDCs for CO PD: From Famine to a Feast of Therapeutic Choices FDCs for CO PD: From Famine to a Feast of Therapeutic Choices LAURA RUNKEL, PhD Associate Director, CNS, AutoImmune/Inflammation, Ophthalmology Historically, there have been few therapies developed for

More information

APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe

APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change

More information

CURRICULUM VITAE FRANCIS J. AVERILL, M.D., J.D. Pulmonary, Critical Care, Sleep Disorders, Allergy & Immunology. Medical Doctor (M.D.

CURRICULUM VITAE FRANCIS J. AVERILL, M.D., J.D. Pulmonary, Critical Care, Sleep Disorders, Allergy & Immunology. Medical Doctor (M.D. CURRICULUM VITAE FRANCIS J. AVERILL, M.D., J.D. Pulmonary, Critical Care, Sleep Disorders, Allergy & Immunology PRIMARY OFFICE ADDRESS: St. Francis Sleep Allergy & Lung Institute 802 N. Belcher Road Clearwater,

More information

Management of COPD Updates and Evidence

Management of COPD Updates and Evidence Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif

More information

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older

Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older The Canadian Thacic Society recommends a tempary, greater

More information

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator

COPD Medicine. No one ever showed me how to use this. Wendy Happel; RRT, COPD Educator Krystal Fedoris; RRT-NPS, BA, COPD Educator Medicine. No one ever showed me how to use this. Wendy Happel; RRT, Educator Krystal Fedoris; RRT-NPS, BA, Educator 1 Taking prescriptions correctly Taking prescriptions can be a challenge Busy schedules

More information

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.

Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution

More information

Foundations of Pharmacology

Foundations of Pharmacology Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids

More information

CSRC COPD Initiative Think Tank meeting Washington DC March 6, 2014

CSRC COPD Initiative Think Tank meeting Washington DC March 6, 2014 What is the role of outcome studies in pulmonary drug development and what data can be collected during development to sufficiently characterize an agent so that an outcome study not necessary? CSRC COPD

More information

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.

glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed

More information

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase

More information

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless?

Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Using Inhaled Corticosteroids as Needed for Asthma: giving patients relief or leaving them breathless? Lindsay Thomas, Pharm.D. PGY2 Ambulatory Care Resident Department of Pharmacotherapy and Pharmacy

More information

Pharmacotherapy for COPD

Pharmacotherapy for COPD 10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in

More information

STRIVERDI RESPIMAT (olodaterol hcl) aerosol

STRIVERDI RESPIMAT (olodaterol hcl) aerosol STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Asthma/COPD Update with Inhaler Workshop

Asthma/COPD Update with Inhaler Workshop Asthma/COPD Update with Inhaler Workshop October 8, 2017 Nathan Samsa, DO, Pharm D, RPh, FACOI None Disclosures Agenda Asthma Updates COPD Updates Inhaler Workshop Medication Acronyms SABA: Short acting

More information

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES:

DATE: 09 December 2009 CONTEXT AND POLICY ISSUES: TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY

More information

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop

INHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers

More information

Study No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS

Study No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate

More information

Potential risks of ICS use

Potential risks of ICS use Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk

More information

Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)

Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

NEWER BRONCHODILATORS. Dr R Lakshmi Narasimhan SR Pulmonary Medicine

NEWER BRONCHODILATORS. Dr R Lakshmi Narasimhan SR Pulmonary Medicine NEWER BRONCHODILATORS Dr R Lakshmi Narasimhan SR Pulmonary Medicine Topics to be covered Ultra LABA (+/-ICS) Newer LAMA LAMA + LABA Novel Bronchodilators Why the need for newer BD? OD dosing convenient

More information

Delivering Aerosol Medication in ICU

Delivering Aerosol Medication in ICU Delivering Aerosol Medication in ICU 18th Aug 2017 Lau Chee Lan Pharmacist HCTM PPUKM ASMIC 2017 Aerosol Therapy Part of the treatment for a variety of respiratory disease * asthma and chronic obstructive

More information

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device

Question I was one of the first dry power devices available in the US Flovent, Serevent and Advair are all available in this device What Device am I Class Side Effects History Potpourri Monitoring Tools 10 10 10 10 10 20 20 20 20 20 30 30 30 30 30 40 40 40 40 40 50 50 50 50 50 WHAT KIND OF DEVICE AM I? I was one of the first dry power

More information

Co. Durham & Darlington Respiratory Network COPD Treatment Guide

Co. Durham & Darlington Respiratory Network COPD Treatment Guide Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination

More information

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol

AIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Improving Outcomes in COPD

Improving Outcomes in COPD Neil MacIntyre MD Duke University Durham NC Current treatment guidelines f COPD focus Barriers to providing optimal treatment Diagnosis of COPD EXPOSURE TO RISK FACTORS AND/ OR SYMPTOMS sputum cough dyspnea

More information

SYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004

SYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004 Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled

More information

Disclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015

Disclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015 Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation

More information